scholarly journals Multiple Primary Malignancies in Renal Transplant Recipients: a Single Centre Retrospective Cohort Study

2018 ◽  
Vol 43 (3) ◽  
pp. 1034-1041 ◽  
Author(s):  
Nikolina Basic-Jukic ◽  
Jason Kirincich ◽  
Bojan Jelakovic ◽  
Zeljko Kastelan
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Single Centre ◽  
Multiple Primary Malignancies ◽  
Multiple Primary

scholarly journals Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study

2010 ◽  
Vol 3 (suppl 2) ◽  
pp. ii32-ii36 ◽  
Author(s):  
M. Gonzalez-Molina ◽  
M. A. Gentil ◽  
D. Burgos ◽  
M. Cabello ◽  
C. Cobelo ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Renal Transplant Recipients ◽  
Steroid Withdrawal ◽  
Transplant Recipients

scholarly journals A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0178801 ◽  
Author(s):  
Lilli Gard ◽  
Willem van Doesum ◽  
Hubert G. M. Niesters ◽  
Willem J. van Son ◽  
Arjan Diepstra ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Delicate Balance ◽  
Bk Polyomavirus

scholarly journals Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study

PRILOZI ◽  
2020 ◽  
Vol 41 (2) ◽  
pp. 49-55
Author(s):  
Nikolina Basic-Jukic ◽  
Vesna Furic-Cunko ◽  
Ivana Juric
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Hematological Parameters ◽  
Graft Function ◽  
Bleeding Event ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Anticoagulant Drugs

AbstractAim: Data on the use of novel anticoagulant drugs (NOACc) in renal transplant recipients is scarce. The aim of our study was to investigate the safety and efficacy of NOACs in renal transplant recipients.Materials and Methods: In a single-centre retrospective cohort study we assessed adverse reactions, thromboembolic events, and interactions of calcineurin inhibitors in patients treated with NOACs.Results: Twenty-three renal transplant recipients were treated with NOACs (70% male), mean age of 65.8 ± 1.8 years. Fourteen (61%) patients were treated with rivaroxaban, apixaban was given to 8 (35%) of our patients, and dabigatran to one patient (4%). The main indications for NOAC therapy was atrial fibrillation in 61% and deep venous thrombosis in 23% of patients. Bleeding occurred in 2 patients (1 treated with rivaroxaban and 1 with dabigatran). None of our patients developed thrombosis while treated with NOAC. During the median follow-up of 24 months graft function, as well as hematological parameters, remained stable in patients that were treated with rivaroxaban and apixaban, while dabigatran was ceased after a month of therapy due to a bleeding event.Conclusion: Our results show that both rivaroxaban and apixaban are safe and efficient oral anticoagulant drugs in renal transplant patients. Additional studies are needed to prove these results.

scholarly journals Former smoking and early and long-term graft outcome in renal transplant recipients: a retrospective cohort study

2017 ◽  
Vol 30 (2) ◽  
pp. 187-195 ◽  
Author(s):  
Steven Van Laecke ◽  
Evi Vanessa Nagler ◽  
Patrick Peeters ◽  
Francis Verbeke ◽  
Wim Van Biesen
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Graft Outcome

scholarly journals 1674. Epidemiology of Urinary Tract Infections in the Renal Transplant Population in a Large Urban Midwestern Hospital: A Retrospective Cohort Study

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S822-S823
Author(s):  
Rebecca Nirmal Kumar ◽  
Teresa Zembower ◽  
Valentina Stosor
Keyword(s):  
Cohort Study ◽  
Urinary Tract ◽  
Renal Transplant ◽  
Urinary Tract Infections ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Multidrug Resistant ◽  
Renal Transplant Recipients ◽  
Care Hospital ◽  
Tract Infections

Abstract Background Renal Transplant Recipients (RTR) are at high risk for Urinary Tract Infections (UTIs). However, the best empiric option for treatment is not well defined, because the prevalence of extended spectrum beta-lactamase (ESBL) Enterobacteriaceae and carbapenem resistant Enterobacteriaceae (CRE). The primary purpose of this study was to describe the prevalence of multidrug resistant UTIs in a contemporary cohort of RTR at a large Midwestern tertiary care hospital. Secondary outcomes evaluated frequency of key symptoms and physical exam findings, as well as characteristics of patients who developed multidrug resistant organisms, morbidity, and mortality. Methods This was a single-center retrospective cohort study. Patients were included if they were 18 years or older and underwent their transplant between July 11, 2019 and November 26, 2018. Statistical analysis was performed using Fischer’s Exact T-test for comparison of the patients with and without ESBL UTIs. Significance was defined by a p< 0.05 Results Two hundred fifty-two patients were evaluated (median age 54.4, 38.3% female gender), 36 patients developed UTIs, and no patients had CRE organisms. ESBL UTI prevalence was 7/252 (2.8%) among the total RTR population and 7/36 (19.4%) among the population of RTR who developed UTIs. Mortality rates did not differ significantly between patients with and without ESBL UTI (0% and 6.9%, respectively, p=.489) (Table 1). Additional clinical characteristics of the patients that developed ESBL UTIs were also obtained (Table 2). Table 1: Comparison of non-ESBL UTI and ESBL UTI Table 2: Characteristics of Patients with ESBL UTI Conclusion Prevalence of ESBL UTIs among RTR are low at a tertiary Midwestern hospital. Disclosures All Authors: No reported disclosures

Hemoglobin and Cholesterol Affect Apparent Tacrolimus Clearance in Pediatric Transplant Recipients – a Retrospective Cohort Study

2021 ◽  
Vol 4 (2) ◽  
pp. 01-07
Author(s):  
Carmen Cuellar
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Area Under The Curve ◽  
Hdl Cholesterol ◽  
Therapeutic Index ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Pediatric Renal Transplant ◽  
The Impact

Introduction: Tacrolimus has a narrow therapeutic index with substantial inter- and intra-patient variability. Factors beyond genetic and developmental factors are poorly understood. Recent adult studies suggest that hemoglobin affects the apparent clearance (CL/F), whereas this and other potential factors in children are understudied. Methods: After ethics approval, we performed a single center retrospective cohort study of pediatric renal transplant recipients, who were followed between January 1st, 2004, and June 30th, 2018. Patients without tacrolimus therapy or concomitant sirolimus were excluded. The aim was to show the impact of hemoglobin, albumin, cholesterol and HDL on the apparent tacrolimus clearance (CL/F = Dose/AUC). Data were collected from electronic health record. We used 12-point pharmacokinetic (PK) profiles. Results: Thirty-three patients were included. Median age at transplantation was 10 years, 52% were female, the median tacrolimus area under the curve (AUC) was 133 ng*h/mL. CL/F mainly correlated with hemoglobin (n=1,257, r=-0.3767, p<0.0001), HDL-cholesterol (n=236, r=-0.3973, p<0.0001) and total cholesterol (n=373, r=-0.1821, p=0.0004). Conclusion: The present study suggests a moderate impact of the biochemical factors studied in the tacrolimus CL/F. Lower hemoglobin seems to increase it, while higher cholesterol decreases it. Physicians should be aware of this association during the TDM follow up.

Sign in / Sign up

Export Citation Format

Share Document